CDK12 and prostate carcinoma: As mentioned, CDK12-altered prostate cancers typically carry poor prognosis and do not respond well to PARP inhibition, yet they present increased neoantigen load and lymphocytic infiltration, which may increase responsiveness to anti-PD1 therapy[25,27].